Global Benign Prostatic Hyperplasia Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Benign Prostatic Hyperplasia Treatment Market size is anticipated to expand from USD 7.86 billion to USD 16.09 billion, demonstrating a CAGR of around 5.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of benign prostatic hyperplasia treatment is estimated at USD 8.22 billion.
In October 2024, NLM published an article stating that the histological incidence of BPH at autopsy in males is between 50% to 60% in their 60s, accelerating to 80% to 90% of those older than 70 years of age. BPH is a common disorder experienced by aging men and a frequent cause of lower urinary tract symptoms. According to Johns Hopkins Medicine, as many as 200,000 prostatectomy procedures are carried out yearly in the U.S. for BPH. Furthermore, in June 2024, the National Institute of Diabetes and Digestive and Kidney Diseases stated that BPH rarely causes symptoms in men younger than age 40, yet, it is the most common prostate problem in men older than age 50.
The global market is majorly driven by the rising geriatric population, prevalence of lifestyle-related conditions such as obesity and diabetes, and technological innovations including laser therapies, drug formulations, and prostatic implants. In May 2024, Teleflex Incorporated presented multiple clinical studies at the 2024 American Urological Association Annual Meeting. These studies add to the clinical evidence around the safety, efficacy and patient experience with a Prostatic Urethral Lift (PUL) using the UroLift System for benign BPH.
